Acetylspiramycin Tablets

Acetylspiramycin is an acetylated derivative of spiramycin and belongs to the 16-membered macrolide class. This product has good antibacterial effects on Gram-positive cocci such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Enterococcus faecalis. It also has inhibitory effects on Listeria, Moraxella catarrhalis, Neisseria gonorrhoeae, Campylobacter fetus, Haemophilus influenzae, Legionella pneumophila, Bordetella pertussis, Bacteroides, Clostridium perfringens, Propionibacterium acnes, Peptococcus and Streptococcus, as well as Chlamydia, Mycoplasma, Toxoplasma, Cryptosporidium, etc. Intestinal Gram-negative bacilli are usually resistant. The mechanism of action is that acetylspiramycin binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibiting RNA-dependent protein synthesis and exerting an antibacterial effect.

Monoacetylspiramycin II, monoacetylspiramycin III, diacetyl

This product is a sugar-coated tablet or a film-coated tablet. After removing the coating, it appears off-white or slightly yellow.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal cavity infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

Patients tolerated the drug well. Adverse reactions mainly included gastrointestinal reactions such as abdominal pain, nausea, and vomiting, which often occurred when taking large doses. Most of them were mild and disappeared on their own after stopping the drug. Allergic reactions were rare, mainly drug eruptions. No liver or kidney damage or abnormal blood or urine routine tests were found.

Patients who are allergic to this product, erythromycin, or other macrolides are contraindicated.

Precautions for children: The efficacy and safety of pediatric patients under 6 months old have not been determined. Precautions for pregnancy and lactation: This product can penetrate the placenta, so the use of it in pregnant women needs to be determined after fully weighing the pros and cons. There is no data showing whether acetylspiramycin is excreted through breast milk, but since many macrolide drugs can be excreted through breast milk, lactating women should use this product with caution. If it must be used, breastfeeding should be suspended. Precautions for the elderly: Elderly patients with normal liver and kidney function do not need to reduce the dosage.

1. This product does not affect the metabolism of aminophylline and other drugs in the body. 2. In patients receiving ergot derivatives, ergot poisoning has occurred when certain macrolides are used at the same time. There are currently no reports of ergot and acetylspiramycin interacting, but this possibility still exists in theory. Therefore, acetylspiramycin and ergot should not be taken at the same time.

Sealed, store in a cool, dark and dry place

0.1g (100,000 units)

24 months